Published On: Wed, Oct 19th, 2016

Analyst Coverage: Johnson & Johnson (NYSE:JNJ)


Recently stock market analysts have updated their consensus ratings on shares of Johnson & Johnson (NYSE:JNJ).

Most recent broker ratings

09/28/2016 – Johnson & Johnson had its “buy” rating reiterated by analysts at UBS. They now have a USD 137 price target on the stock.

09/19/2016 – Johnson & Johnson had its “neutral” rating reiterated by analysts at Credit Suisse. They now have a USD 123 price target on the stock.

08/30/2016 – Johnson & Johnson had its “neutral” rating reiterated by analysts at BTIG Research.

08/18/2016 – Johnson & Johnson had its “buy” rating reiterated by analysts at Deutsche Bank. They now have a USD 142 price target on the stock.

07/20/2016 – Johnson & Johnson was upgraded to “buy” by analysts at Argus. They now have a USD 145 price target on the stock.

07/20/2016 – Johnson & Johnson had its “outperform” rating reiterated by analysts at RBC Capital. They now have a USD 133 price target on the stock.

07/20/2016 – Johnson & Johnson had its “outperform” rating reiterated by analysts at BMO Capital Markets. They now have a USD 132 price target on the stock.

07/19/2016 – Johnson & Johnson had its “outperform” rating reiterated by analysts at Leerink Swann. They now have a USD 140 price target on the stock.

07/08/2016 – Johnson & Johnson had its “overweight” rating reiterated by analysts at Barclays. They now have a USD 125 price target on the stock.

06/14/2016 – Johnson & Johnson had its “hold” rating reiterated by analysts at Jefferies. They now have a USD 109 price target on the stock.

05/20/2016 – Standpoint Research began new coverage on Johnson & Johnson giving the company a “sell” rating. They now have a USD 94 price target on the stock.

05/19/2016 – Johnson & Johnson had its “outperform” rating reiterated by analysts at Raymond James. They now have a USD 120 price target on the stock.

04/20/2016 – Johnson & Johnson had its “neutral” rating reiterated by analysts at Piper Jaffray. They now have a USD 106 price target on the stock.

04/20/2016 – Johnson & Johnson had its “neutral” rating reiterated by analysts at Goldman Sachs. They now have a USD 114 price target on the stock.

04/06/2016 – Societe Generale began new coverage on Johnson & Johnson giving the company a “hold” rating. They now have a USD 113 price target on the stock.

Johnson & Johnson has a 50 day moving average of 118.58 and a 200 day moving average of 117.61. The stock’s market capitalization is 315.75B, it has a 52-week low of 94.28 and a 52-week high of 126.07.

The share price of the company (NYSE:JNJ) was down -2.60%, with a high of 118.48during the day and the volume of Johnson & Johnson shares traded was 12598256.

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. The Company’s segments include Consumer, Pharmaceutical and Medical Devices. The Consumer segment includes a range of products used in the baby care, oral care, skin care, over-the-counter pharmaceutical, women’s health and wound care markets. The Pharmaceutical segment is focused on over five therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, and cardiovascular and metabolic diseases. The Medical Devices segment includes a range of products used in the orthopedic, surgery, cardiovascular, diabetes care and vision care fields. Its research facilities are located in the United States, Belgium, Brazil, Canada, China, France, Germany, India, Israel, Japan, the Netherlands, Singapore, Switzerland and the United Kingdom.